Gamida Cell Ltd. announced today a collaboration agreement with Cordis unit Biologics Delivery Systems. Biologics will supply catheters for the upcoming Phase I/II clinical trial of Gamida Cell’s CardioCure product for the treatment of post-myocardial infarction (heart attack) patients.
CardioCure is a proprietary ex-vivo expanded autologous bone marrow product. The clinical trial, which will be conducted in Israel, is to evaluate the safety and efficacy of CardioCure.
CardioCure will be injected directly into the myocardium of 48 heart attack patients using the latest generation of Biologics Delivery Systems’ NOGA cardiac navigation system and MyoStar injection catheter.
"The NOGA XP cardiac navigation system is a highly sophisticated and accurate electro-guided methodology, which creates precise, 3-dimensional images of the heart. This will enable us to identify damaged myocardial tissue and accurately deliver the CardioCure injections into the relevant area in order to assist with functional restoration of the damaged heart," said Professor Ran Kornowski, Director of Interventional Cardiology and Cardiac Catheterization Laboratories at the Rabin Medical Center and a leading principal investigator in the Gamida Cell CardioCure clinical study.
Gamida Cell develops treatments for debilitating and often fatal illnesses such as cancer, cardiac disease and peripheral vascular disease. The company uses human stem cells from umbilical cord blood and bone marrow
Current shareholders include Biomedical Investments Ltd., Israel Healthcare Ventures, Elbit Imaging, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), Denali Ventures Fund, and Auriga Partners.
Published by Globes [online], Israel business news - www.globes-online.com - on July 14, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008